Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: EGFR-MET bispecific antibodies
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

EGFR-MET bispecific antibodies

4 evidence topics · 4 sources

Pan-Asian adapted ESMO guideline

“Amivantamab combined with platinum-based ChT is recommended for the treatment of EGFR exon 20 insertion-mutated NSCLC in the first-line setting” (opens the source at this quote in a new tab)

Comparator regulatory information: amivantamab

“approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment” (opens the source at this quote in a new tab)
“traditional approval to amivantamab-vmjw” (opens the source at this quote in a new tab)

First-line amivantamab plus chemotherapy: progression-free survival and response

“Progression-free survival was significantly longer in the amivantamab–chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively; hazard ratio for disease progression or death, 0.40; 95% confidence interval [CI], 0.30 to 0.53; P<0.001).” (opens the source at this quote in a new tab)
“At 18 months, progression-free survival was reported in 31% of the patients in the amivantamab–chemotherapy group and in 3% in the chemotherapy group; a complete or partial response at data cutoff was reported in 73% and 47%, respectively (rate ratio, 1.50; 95% CI, 1.32 to 1.68; P<0.001).” (opens the source at this quote in a new tab)
“In the interim overall survival analysis (33% maturity), the hazard ratio for death for amivantamab–chemotherapy as compared with chemotherapy was 0.67 (95% CI, 0.42 to 1.09; P=0.11).” (opens the source at this quote in a new tab)

First-line amivantamab plus chemotherapy: toxicity and treatment discontinuation

“The predominant adverse events associated with amivantamab–chemotherapy were reversible hematologic and EGFR-related toxic effects; 7% of patients discontinued amivantamab owing to adverse reactions.” (opens the source at this quote in a new tab)
“The incidence of infusion-related reactions was 42% in the amivantamab–chemotherapy group and 1% in the chemotherapy group.” (opens the source at this quote in a new tab)
“The most common grade 3 or higher adverse events were neutropenia (in 33%), leukopenia (in 11%), and rash (in 11%) with amivantamab–chemotherapy and neutropenia (in 23%), anemia (in 12%), and thrombocytopenia (in 10%) with chemotherapy.” (opens the source at this quote in a new tab)
“Serious adverse events were reported in 37% of the patients in the amivantamab–chemotherapy group and in 31% of those in the chemotherapy group” (opens the source at this quote in a new tab)